Sanctuary Advisors LLC Purchases Shares of 31,040 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Sanctuary Advisors LLC acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 3rd quarter, HoldingsChannel reports. The fund acquired 31,040 shares of the biopharmaceutical company’s stock, valued at approximately $667,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Hohimer Wealth Management LLC purchased a new stake in Catalyst Pharmaceuticals during the third quarter worth approximately $329,000. Vestcor Inc lifted its position in shares of Catalyst Pharmaceuticals by 18.4% during the 3rd quarter. Vestcor Inc now owns 60,431 shares of the biopharmaceutical company’s stock worth $1,201,000 after buying an additional 9,379 shares during the last quarter. Barclays PLC boosted its holdings in shares of Catalyst Pharmaceuticals by 129.4% in the 3rd quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company’s stock valued at $4,939,000 after buying an additional 140,129 shares in the last quarter. XTX Topco Ltd grew its position in shares of Catalyst Pharmaceuticals by 73.3% in the 3rd quarter. XTX Topco Ltd now owns 19,294 shares of the biopharmaceutical company’s stock valued at $384,000 after buying an additional 8,160 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth $216,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Gary Ingenito sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now owns 51,391 shares in the company, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Molly Harper sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock valued at $1,754,140 over the last three months. 11.00% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Trading Up 0.1 %

Shares of CPRX stock opened at $21.62 on Wednesday. The company has a market capitalization of $2.58 billion, a P/E ratio of 18.32, a price-to-earnings-growth ratio of 3.35 and a beta of 0.75. The business’s 50 day moving average is $21.80 and its two-hundred day moving average is $19.46. Catalyst Pharmaceuticals, Inc. has a twelve month low of $13.12 and a twelve month high of $24.27.

Analyst Upgrades and Downgrades

CPRX has been the subject of several research analyst reports. StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Stephens started coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price target on the stock. Truist Financial lifted their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Buy” and an average price target of $31.14.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.